N/A N=9 Early Feasibility of the Branched TAG® Device in the Treatment of Aortic Arch Aneurysms
Aneurysm of Aortic Arch
Primary: Number of Participants With Successful Study Device Access — 9 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Endovascular Repair for the Descending Thoracic Aorta
Aorta Thoracic; Traumatic Rupture
Primary: Number of Participants With Major Adverse Events — 0 number of serious adverse events
N/A N=21 ARISE: Evaluation of the GORE® Ascending Stent Graft in the Treatment of DeBakey Type I/II Aortic Dissection
Aortic Dissection
Primary: All Cause Mortality at 30 Days Post-procedure — 3 Participants
N/A N=31 Feasibility Study for GORE® TAG® Thoracic Branch Endoprosthesis to Treat Proximal Descending Thoracic Aortic Aneurysms
Aortic Aneurysm, Thoracic
Primary: Number of Participants With Successful Study Device Access — 31 Participants
N/A N=10 GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Type IV Thoracoabdominal Aortic Aneurysms
Thoracoabdominal Aortic Aneurysm
Primary: Absence of the Following Procedural Safety Events: Death, Stroke, Myocardial Infarction, Bowel Ischemia, Paraplegia, Respiratory Failure, Renal Failure, Procedural Blood…
N/A N=19 34mm Cuff Study for Endovascular Repair of Abdominal Aortic Aneurysms
Abdominal Aortic Aneurysm
Primary: Number of Participants With Proximal Type I Endoleak at Each Timepoint — 1; 0; 0; 0 Participants
N/A N=50 Evaluation of the GORE Conformable TAG® Thoracic Endoprosthesis for Treatment of Acute Complicated Type B Aortic Dissection
Type B Aortic Dissection
Primary: All-cause Mortality Incidence Through 30 Days Post-treatment — 5 participants — p=.006
Phase 3 N=25 Cerebral Oximetry and Neurological Outcomes in Aortic Arch Surgery Patients
Postoperative Cognitive Dysfunction
Primary: Mini Mental State Examination (MMSE) — 27; 26.769 scores on a scale — p=0.678
N/A N=51 Thoracic Endoprosthesis for Treatment of Aneurysm of the Descending Thoracic Aortic
Aneurysm
Primary: The Number of Subjects Free From a Major Device Event Through 1 Month Post-treatment — 50 participants — p=0.0024
N/A N=10 Visceral Manifold Study for the Repair of Thoracoabdominal Aortic Aneurysms
Thoracoabdominal Aortic Aneurysms
Primary: Freedom From Major Adverse Events (MAE) at Day 30 — 3; 4 Participants
Phase 2 N=23 GORE TAG® Thoracic Endoprosthesis - 45 mm for the Treatment of Aneurysms of the Descending Thoracic Aorta
Aortic Aneurysm, Thoracic
Primary: Freedom From Major Adverse Events and Major Device Events Through 1 Year Post-treatment — 11 Participants
N/A N=1,366 Endovascular Exclusion of TAAA/AAA Utilizing Fenestrated/Branched Stent Grafts
Thoracoabdominal Aneurysm · Abdominal Aortic Aneurysm
Primary: Freedom From Aneurysm Rupture — 22 Participants
Phase 2 N=55 Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair
Surgical Procedures
Primary: Change From Baseline to Peak in Cerebrospinal Fluid (CSF) S100 Beta Within 48 Hours Following Descending Thoracic Aorta/Thoracoabdominal Aortic Aneurysm (DTA/TAAA)…
N/A N=44 Suprarenal Proximal Cuff Study for Treatment of Abdominal Aortic Aneurysm
Abdominal Aortic Aneurysm
Primary: Number of Subjects With Proximal Type I Endoleak — 2 Participants
N/A N=40 PRESERVE-Zenith® Branch Endovascular Graft-Iliac Bifurcation Clinical Study
Aortoiliac Aneurysms · Iliac Aneurysms
Primary: Number of Patients With Freedom From Patency-related Intervention Defined as a Secondary Intervention to Treat a > 60 % Stenosis of the Internal Iliac Artery Associated…
Phase 3 N=100 To Evaluate the Safety and Efficacy for GORE TAG Thoracic Endoprosthesis in the Treatment of Thoracic Aortic Disease
Aneurysm, Dissecting · Aortic Aneurysm, Thoracic
Primary: Percentage of Participants With Technically Successful Implant — 99.0 percentage of participants
N/A N=15 Guo's Visceral Arteries Reconstruction: First in Man Study
Thoracoabdominal Aortic Aneurysm · Pararenal Aortic Aneurysm
Primary: Number of Participants With Major Adverse Events (MAE) Within 30 Days Postoperative — 1 participants
N/A N=401 Endovascular Exclusion of Abdominal Aortic Aneurysms in High Risk Patients
Abdominal Aortic Aneurysm · Iliac Aneurysm · Internal Iliac Aneurysm
Primary: Freedom From Aneurysm Rupture — 0 Participants
Phase 2 N=224 AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK)
Abdominal Aortic Aneurysm
Primary: Change in the Growth Rate of Abdominal Aortic Aneurysm — 1.77; 1.81; 1.66 mm — p=0.78
N/A N=88 Angiotensin II Pathway and Postoperative Hypoxemia
Aortic Dissection
Primary: The Difference Concentrations of ANG II in Serum Between Patients With and Without Postoperative Hypoxemia. — 100; 78.5 pg / mL
N/A N=100 LSA Reconstruction With Laser Fenestration During the TEVAR
Type B Aortic Dissection
Primary: Freedom From All-cause Reintervention, All-cause Mortality and Major Adverse Events Within 30 Days After Procedure — 84 Participants
N/A N=613 Immediate Management of the Patient With Rupture : Open Versus Endovascular Repair
Abdominal Aortic Aneurysm
Primary: Mortality — 111; 112; 133; 130 Participants
N/A N=150 Evaluation of the GORE TAG Thoracic Endoprosthesis in the Treatment of Aneurysms
Aortic Aneurysm, Thoracic
Primary: Aneurysm Related Death — 4 participants
N/A N=61 A European Study on Medical Management Versus TAG Device + Medical Management for Acute Uncomplicated Type B Dissection
Aortic Diseases
Primary: Composite of Partial or No False Lumen Thrombosis, Aortic Rupture, and Aortic Dilatation — 15; 31 participants — p=<0.001
Phase 2 N=35 Study of the Large Diameter GORE EXCLUDER® AAA Endoprosthesis in Abdominal Aneurysms
Aortic Aneurysm, Abdominal
Primary: Time to First Major Adverse Event Experienced by Subjects From the Time of Treatment Through 1 Year — 84.0 days — p=0.003
N/A N=160 Valor II: The Valiant Thoracic Stent Graft System Clinical Study
Thoracic Aortic Aneurysm
Primary: Percentage of Participants That Did NOT Experience Aneurysm-Related Mortality (Post-market Primary Endpoint) — 94.8 Percentage of participants
N/A N=14 Modified Perfusion for Neonatal Aortic Arch Reconstruction
Aortic Arch Hypoplasia or Atresia
Primary: Intestinal Fatty Acid Binding Protein and C-reactive Protein
N/A N=64 Study of Aortic Root Reimplantation Procedure
Ascending Aortic Aneurism · Aortic Valve Insufficiency
Primary: Freedom From Aortic Insufficiency More Than 2+ (Percentage, Kaplan-Meier) — 88.2; 87.7 percentage of participants
Phase 4 N=881 Standard Open Surgery Versus Endovascular Repair of Abdominal Aortic Aneurysm (AAA)
Aortic Aneurysm
Primary: All-cause Mortality — 146; 146 participants — p=0.81
N/A N=51 Evaluation of the GORE Conformable TAG® for Treatment of Traumatic Transection
Thoracic Injuries
Primary: All Cause Mortality — 4 participants